EODData

MEMBERSHIP REGISTER LOG IN

FRA, P731: MEDEXUS PHARMACEUTIC.

21 Nov 2025
LAST:

1.530

CHANGE:
 0.02		OPEN:
1.530		HIGH:
1.530		ASK:
0.000		VOLUME:
2.9K
CHG(%):
1.29		PREV:
1.550		LOW:
1.530		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Nov 251.5301.5301.5301.5302.9K
20 Nov 251.5501.5501.5501.5502.9K
19 Nov 251.6001.6001.6001.6002.9K
18 Nov 251.5901.5901.5901.5902.9K
17 Nov 251.5701.5701.5701.5702.9K
13 Nov 251.5901.7301.5901.7302.9K
12 Nov 251.5801.5801.5801.5802.5K
11 Nov 251.5801.5801.5801.5802.5K
07 Nov 251.5601.5601.5601.5602.5K
06 Nov 251.5701.5701.5701.5700

PROFILE

Name:MEDEXUS PHARMACEUTIC.
About:Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2018 and is based in Toronto, Canada.
Sector:Healthcare
Address:10 King Street East, Toronto, ON, Canada, M5C 1C3
Website:https://www.medexus.com
ISIN:CA58410Q2036

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:83.00 
Forward P/E:13.93 
PEG Ratio:-1.11 
Price to Sales:0.53 
Price to Book:1.01 
Profit Margin:0.01 
Operating Margin:0.03 
Return on Assets:0.04 
Return on Equity:0.02 
Revenue:91.71M 
EBITDA:14.44M 
Shares:32.26M 
Market Cap:49.36M 

TECHNICAL INDICATORS

MA5:1.572.5%
MA10:1.593.7%
MA20:1.636.5%
MA50:1.689.8%
MA100:1.7111.7%
MA200:1.7312.9%
RSI14:40.00 
WPR14:-100.00 
MTM14:-0.15
ROC14:-0.09 
ATR:0.05 
Week High:1.604.6%
Week Low:1.530.0%
Month High:1.7514.4%
Month Low:1.5312.9%
Year High:3.53130.7%
Year Low:1.2324.2%
Volatility:19.67 

RECENT SPLITS

Date Ratio
19 Dec 20181-15